Neuroprotection by Drugs, Nutraceuticals and Physical Activity

Abstract

Acute and chronic neural injuries, including stroke, brain trauma and neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS), Huntington’s disease (HD), Parkinson’s disease (PD), and Alzheimer’s disease (AD) are associated with high morbidity and mortality rates [...]

Biobased nanoemulsions for targeted drug delivery to treat dementia and aging

“…[28]) when used as a multitasking (drugcarrying) therapeutic vehicle. In 2022 and 2023, several groups of investigators have published arguments/reviews which support using such a multi-factorial approach for the reversal of cognitive decline in late-onset dementia and mild cognitive impairment: for example, Tarozzi and Angeloni [57] stress that neurological disorders are characterized by a multifactorial nature that requires treatment with molecules/ agents capable of targeting multiple pathogenic events. In addition, Powers and Sahoo [58] point out that SR-BI has been implicated in modulating diabetes risk; this fact is noteworthy since dyslipidemia, diabetes, and atherosclerotic cardiovascular disease are commonly comorbid conditions and are all risk factors for late-onset dementia with aging [58,59].…”